(UroToday.com) The European Association of Urology 2021 Annual Meeting’s Game-Changing session included a presentation by Professor Johann De Bono discussing the VISION trial, a phase 3 study of 177Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer (mCRPC). As PSMA is highly expressed in prostate cancer and mCRPC lesions, the combination of PSMA-617 with the beta-emitter lutetium allows for the targeted delivery of ß-particle radiation to PSMA-expressing cells and the surrounding microenvironment.